Hedge Fund and Insider Trading News: Bill Ackman, Izzy Englander, Warren Buffett, Ray Dalio, Starboard Value LP, Silver Lake Partners, Repligen Corporation (RGEN), Bausch Health Companies Inc (BHC), and More

Page 2 of 2

Wednesday 5/27 Insider Buying Report: NREF, TJX (Nasdaq.com)
At NexPoint Real Estate Finance, a filing with the SEC revealed that on Friday, President James D. Dondero purchased 12,900 shares of NREF, at a cost of $14.16 each, for a total investment of $182,637. So far Dondero is in the green, up about 20.0% on their buy based on today’s trading high of $16.99. NexPoint Real Estate Finance is trading up about 1.3% on the day Wednesday. Before this latest buy, Dondero purchased NREF on 3 other occasions during the past twelve months, for a total investment of $1.24M at an average of $11.88 per share. And also on Friday, Director Rosemary T. Berkery purchased $160,432 worth of TJX Companies, purchasing 3,000 shares at a cost of $53.48 a piece. TJX Companies is trading down about 0.2% on the day Wednesday. Berkery was up about 6.0% on the purchase at the high point of today’s trading session, with TJX trading as high as $56.68 at last check today.

A Director at Repligen (NASDAQ: RGEN) is Buying Shares (Analyst Ratings)
Yesterday, a Director at Repligen (RGEN), Nicolas Barthelemy, bought shares of RGEN for $142.8K. Following Nicolas Barthelemy’s last RGEN Buy transaction on August 31, 2018, the stock climbed by 78.5%. Following this transaction Nicolas Barthelemy’s holding in the company was increased by 59.18% to a total of $355.2K.

Bausch Health Inc (BHC) CHAIRMAN & CEO Joseph C Papa Bought $699,300 of Shares (Guru Focus)
CHAIRMAN & CEO of Bausch Health Inc., Joseph C Papa, bought 30,000 shares of BHC on 09/13/2019 at an average price of $23.31 a share. The total cost of this purchase was $699,300. Valeant Pharmaceuticals International Inc is a specialty pharmaceutical and medical device company which develops, manufactures, and markets a range of generic and branded generic pharmaceuticals, over-the-counter products and medical devices.

Ex-Citi Banker’s Alleged Ties at Issue in Insider Trading Appeal (AFR.com)
When prosecutors knew about possible links between a former Citigroup banker and a wealthy businessman will be one of the issues reviewed during an appeal in the UK’s highest-profile insider trading case. Walid Choucair, a day trader, and Fabiana Abdel-Malek, a former UBS Group AG compliance officer, won the right to appeal on grounds that a potentially important alternative source of information on a series of M&A deals may have been wrongly withheld, according to people familiar with the matter. It’s one of seven grounds that were accepted for argument by the Court of Appeal.

COVID-19 Insider Trading Update (Fox26MedFord.com)
WASHINGTON, D.C. (NBC) – The Justice Department closed insider trading investigations into three senators who sold off stocks following early briefings on the coronavirus. Republican Senator Kelly Loeffler of Georgia was one of four senators the DOJ focused on in connection with stock sales made after early briefings on the virus. She said she is not involved in such decisions, which are made by a third party. Oklahoma Republican James Inhofe, who was also a focus of the probe, says he too is not involved in his investment decisions. California Democrat Dianne Feinstein’s husband made the stock trade in question. She said her assets are in a blind trust.

Private Equity Firm Ares Management LLC Charged With Compliance Failures (HedgeCo.Net)
(HedgeCo.Net) Ares Management LLC, a Los Angeles-based private equity firm and registered investment adviser, has agreed to pay one million dollars to settle charges that it failed to implement and enforce policies and procedures reasonably designed to prevent the misuse of material nonpublic information. The SEC’s order finds that, in 2016, Ares invested several hundred million dollars in a public company through a loan and equity investment that allowed Ares to appoint a senior employee to the company’s board. The order finds that Ares’s compliance policies failed to account for the special circumstances presented by having an employee serve on the portfolio company’s board while that employee continued to participate in trading decisions regarding the portfolio company.

Page 2 of 2